MedTrace Logo

Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection

NCT04603664 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-09-13

No results posted yet for this study

Summary

Recent different biomarkers of acute kidney injury (AKI) have been manufactured by pharmaceutical industry. Studies proved that Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin c are effective predictive biomarkers for early acute kidney injury in septic patients and in children after cardiopulmonary bypass. This study hypothesize that both cystatin c and Neutrophil gelatinase-associated lipocalin can predict AKI in patients with COVID-19 before elevation of serum urea and creatinine which may help early interference.

Conditions

  • Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19

Interventions

DIAGNOSTIC_TEST

serum NGAL and cystatin c

measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • sanaa wasfy · lecturer

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603664 on ClinicalTrials.gov